These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 1379966

  • 1. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA.
    Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
    [Abstract] [Full Text] [Related]

  • 2. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG.
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [Abstract] [Full Text] [Related]

  • 3. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A, Dawes J.
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
    Danhof M, de Boer A, Magnani HN, Stiekema JC.
    Haemostasis; 1992 Jun; 22(2):73-84. PubMed ID: 1379967
    [Abstract] [Full Text] [Related]

  • 5. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.
    Stiekema JC, Van Griensven JM, Van Dinther TG, Cohen AF.
    Br J Clin Pharmacol; 1993 Jul; 36(1):51-6. PubMed ID: 8396956
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman MA.
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
    Ofosu FA, Buchanan MR, Anvari N, Smith LM, Blajchman MA.
    Ann N Y Acad Sci; 1989 Sep; 556():123-31. PubMed ID: 2525356
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
    Zmuda K, Neofotistos D, Ts'ao CH.
    Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.